Surmodics (SRDX) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price objectives for Surmodics' stock. Their SRDX share price forecasts range from $50.00 to $69.00. On average, they predict the company's share price to reach $59.50 in the next twelve months. This suggests a possible upside of 83.4% from the stock's current price.
View analysts price targets for SRDX or view top-rated stocks among Wall Street analysts.

Surmodics' stock was trading at $34.12 at the beginning of 2023. Since then, SRDX stock has decreased by 4.9% and is now trading at $32.44.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our SRDX earnings forecast.

Surmodics, Inc. (NASDAQ:SRDX) released its earnings results on Wednesday, August, 2nd. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.98. The company had revenue of $52.48 million for the quarter, compared to the consensus estimate of $26.70 million. Surmodics had a negative trailing twelve-month return on equity of 8.34% and a negative net margin of 17.58%.

Invesco Nasdaq Future Gen 200 ETF holds 1,909 shares of SRDX stock, representing 0.85% of its portfolio.

Surmodics issued an update on its FY 2023 earnings guidance on Saturday, August, 5th. The company provided earnings per share guidance of -$0.29--$0.14 for the period, compared to the consensus estimate of -$1.30. The company issued revenue guidance of $103.00 million-$106.00 million, compared to the consensus revenue estimate of $116.95 million.

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

Surmodics trades on the NASDAQ under the ticker symbol "SRDX."

Surmodics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.12%), Renaissance Technologies LLC (4.18%), Segall Bryant & Hamill LLC (2.69%), Dimensional Fund Advisors LP (2.63%), Acadian Asset Management LLC (2.11%) and Kennedy Capital Management LLC (2.08%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends.

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRDX stock can currently be purchased for approximately $32.44.

Surmodics (NASDAQ:SRDX) has a market capitalization of $458.38 million and generates $99.95 million in revenue each year. The company earns $-27,270,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis.

The company employs 447 workers across the globe.

Surmodics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The official website for the company is www.surmodics.com. The company can be reached via phone at (952) 500-7000, via email at ir@surmodics.com, or via fax at 952-500-7001.